Antidoping CH

Informations about Antidoping

for more information on the official webside of the Swiss Antipoping

swissantidoping

 

 

2016 Prohibited List
Summary of Major Modifications and Explanatory Notes

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF- COMPETITION)

PROHIBITED SUBSTANCES

S2: Peptide hormones, Growth Factors, Related Substances and Mimetics
Leuprorelin replaced triptorelin as a more universal example of a chorionic

gonadotrophin and luteinizing hormone-releasing factor.

S4. Hormone and Metabolic Modulators

  • Insulin-mimetics were added to the List to include all insulin-receptoragonists.
  • Meldonium (Mildronate) was added because of evidence of its use by athleteswith the intention of enhancing performance.

    S5. Diuretics and Masking Agents

It was clarified that the ophthalmic use of carbonic anhydrase inhibitors is

permitted.

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION

S6. Stimulants:
It was clarified that clonidine is permitted.

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1: Alcohol:

After consideration of the Federation International de Motocyclisme (FIM)’s request, their Federation was removed from the list of sports prohibiting alcohol as a doping agent.
WADA understands that FIM will address the use of alcohol using their own regulations.

MONITORING PROGRAM

Meldonium was removed from the Monitoring Program and added to the Prohibited List.

Hydrocodone, morphine/codeine ratio and tapentadol were removed from the Monitoring Program.

WORLD ANTI-DOPING CODE

INTERNATIONAL STANDARD

PROHIBITED LIST

JANUARY 2016

The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.a, AND PROHIBITED METHODS M1, M2 AND M3.

PROHIBITED SUBSTANCES

S0 NON-APPROVED SUBSTANCES Any pharmacological substance which is not

addressed by any of the subsequent sections of the List and with no current approval by any governmental regula- tory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1 ANABOLIC AGENTS Anabolic agents are prohibited.

1. ANABOLIC ANDROGENIC STEROIDS (AAS) a. Exogenous* AAS, including:

1-Androstenediol (5α-androst-1-ene-3β,17β-diol); 1-Androstenedione (5α-androst-1-ene-3,17-dione); 1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one); 4-Hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); 19-Norandrostenedione (estr-4-ene-3,17-dione); Bolandiol (estr-4-ene-3β,17β-diol );

Bolasterone;
Boldenone;
Boldione (androsta-1,4-diene-3,17-dione);
Calusterone;
Clostebol;
Danazol ([1,2]oxazolo[4′,5′:2,3]pregna-4-en-20-yn-17α-ol); Dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-

17α-methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17α-methyl-5α-

androst-2-en-17β-ol);
Drostanolone;
Ethylestrenol (19-norpregna-4-en-17α-ol); Fluoxymesterone;
Formebolone;
Furazabol (17α-methyl [1,2,5]oxadiazolo[3′,4′:2,3]-5α-

Gestrinone;
Mestanolone;
Mesterolone;
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-

3-one);
Metenolone;
Methandriol;
Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-

androstan-3-one);
Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-

3-one);
Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-

androst-1-en-3-one);
Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-

3-one);
Methyltestosterone;
Metribolone (methyltrienolone, 17β-hydroxy-17α-

methylestra-4,9,11-trien-3-one); Mibolerone;
Nandrolone;
Norboletone;

Norclostebol;
Norethandrolone;
Oxabolone;
Oxandrolone;
Oxymesterone;
Oxymetholone;
Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1’H-

pyrazolo[3,4:2,3]-5α-androstane); Quinbolone;
Stanozolol;
Stenbolone;

Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor- 17α-pregna-4,9,11-trien-3-one);

Trenbolone (17β-hydroxyestr-4,9,11-trien-3-one);

and other substances with a similar chemical structure or similar biological effect(s).

androstan-17β-ol);

2

SUBSTANCES & METHODS

PROHIBITED AT ALL TIMES

(IN- AND OUT-OF-COMPETITION)

b. Endogenous** AAS when administered exogenously: Androstenediol (androst-5-ene-3β,17β-diol);

Androstenedione (androst-4-ene-3,17-dione); Dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); Prasterone (dehydroepiandrosterone, DHEA,

3β-hydroxyandrost-5-en-17-one); Testosterone;

and their metabolites and isomers, including but not limited to:

3β-Hydroxy-5α-androstan-17-one; 5α-Androstane-3α,17α-diol; 5α-Androstane-3α,17β-diol; 5α-Androstane-3β,17α-diol; 5α-Androstane-3β,17β-diol; 5β-Androstane-3α,17β-diol;
7α-Hydroxy-DHEA;
7β-Hydroxy-DHEA;
4-Androstenediol (androst-4-ene-3β, 17β-diol) 5-Androstenedione (androst-5-ene-3,17-dione); 7-Keto-DHEA;

19-Norandrosterone; 19-Noretiocholanolone. Androst-4-ene-3α,17α-diol; Androst-4-ene-3α,17β-diol; Androst-4-ene-3β,17α-diol; Androst-5-ene-3α,17α-diol; Androst-5-ene-3α,17β-diol; Androst-5-ene-3β,17α-diol; Androsterone Epi-dihydrotestosterone; Epitestosterone; Etiocholanolone.

2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and ostarine), tibolone, zeranol and zilpaterol.

For purposes of this section:

* **

“exogenous” refers to a substance which is not ordinarily produced by the body naturally.
“endogenous” refers to a substance which is ordinarily produced by the body naturally.

PEPTIDE HORMONES, GROWTH FACTORS, S2 RELATEDSUBSTANCESANDMIMETICS

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited:

1. Erythropoietin-Receptor agonists:

  1. 1.1  Erythropoiesis-Stimulating Agents (ESAs) including e.g.Darbepoietin (dEPO);
    Erythropoietins (EPO);
    EPO-Fc;
    EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide;

    Methoxy polyethylene glycol-epoetin beta (CERA).

  2. 1.2  Non-erythropoietic EPO-Receptor agonists, e.g. ARA-290;Asialo EPO; Carbamylated EPO.
  1. Hypoxia-inducible factor (HIF) stabilizers, e.g. cobalt and FG-4592; and HIF activators, e.g. argon, xenon.
  2. Chorionic Gonadotrophin (CG) and Luteinizing
    Hormone (LH) and their releasing factors, e.g. buserelin, gonadorelin and triptorelin, in males.
  3. Corticotrophins and their releasing factors, e.g corticorelin.

3

5. Growth Hormone (GH) and its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and ipamorelin; and GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2).

Additional prohibited growth factors:

Fibroblast Growth Factors (FGFs);
Hepatocyte Growth Factor (HGF);
Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs);
Platelet-Derived Growth Factor (PDGF); Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S3 BETA-2 AGONISTS
All beta-2 agonists, including all optical isomers, e.g. d- and l- where relevant, are prohibited.

Except:

  • Inhaled salbutamol (maximum 1600 micrograms over 24 hours);
  • Inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours); and
  • Inhaled salmeterol in accordance with the manufacturers’ recommended therapeutic regimen.The presence in urine of salbutamol in excess of
    1000 ng/mL or formoterol in excess of 40 ng/mL is pre- sumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a con- trolled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

S4 HORMONE AND METABOLIC MODULATORS

The following hormone and metabolic modulators are prohibited:

1. Aromatase inhibitors including, but not limited to: 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide;
Anastrozole;

Androsta-1,4,6-triene-3,17-dione (androstatrienedione); Exemestane;
Formestane;
Letrozole;

Testolactone.

  1. Selective estrogen receptor modulators (SERMs) including, but not limited to:
    Raloxifene;
    Tamoxifen;Toremifene.
  2. Other anti-estrogenic substances including, but not limited to:
    Clomiphene;
    Cyclofenil;Fulvestrant.
  3. Agents modifying myostatin function(s) including, butnot limited, to: myostatin inhibitors.
  4. Metabolic modulators:
    1. 5.1  Activators of the AMP-activated protein kinase(AMPK), e.g. AICAR;
      and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists, e.g. GW 1516;
    2. 5.2  Insulins and insulin-mimetics;
    3. 5.3  Meldonium;
    4. 5.4  Trimetazidine.

4

S5 DIURETICS AND MASKING AGENTS The following diuretics and masking agents are

prohibited, as are other substances with a similar chemical structure or similar biological effect(s).

Including, but not limited to:

  • Desmopressin; probenecid; plasma expanders, e.g. glycerol and intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol.
  • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflu- methiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.Except:
  • Drospirenone; pamabrom; and ophthalmic use ofcarbonic anhydrase inhibitors (e.g. dorzolamide,

    brinzolamide).

  • Local administration of felypressin in dentalanaesthesia.

    The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formo- terol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding unless the Athlete has an approved TUE for that substance in addition to the one granted for the diuretic

    or masking agent.

PROHIBITED METHODS

M1 MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

  1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
  2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen.
  3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2 CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control.

2.

Including, but not limited to:
Urine substitution and/or adulteration, e.g. proteases.

Intravenous infusions and/or injections of more than 50 mL per 6 hour period except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations.

M2 GENE DOPING

The following, with the potential to enhance sport performance, are prohibited:
1. The transfer of polymers of nucleic acids or nucleic

acid analogues;
2. The use of normal or genetically modified cells.

5

IN ADDITION TO THE CATEGORIES S0 TO S5 AND M1 TO M3 DEFINED ABOVE, THE FOLLOWING CATEGORIES ARE PROHIBITED IN-COMPETITION:

PROHIBITED SUBSTANCES

S6 STIMULANTS
All stimulants, including all optical isomers, e.g.

d- and l- where relevant, are prohibited.

Stimulants include:

a: Non-Specified Stimulants:

Adrafinil;
Amfepramone;
Amfetamine;
Amfetaminil;
Amiphenazole;
Benfluorex;
Benzylpiperazine;
Bromantan;
Clobenzorex;
Cocaine;
Cropropamide;
Crotetamide;
Fencamine;
Fenetylline;
Fenfluramine;
Fenproporex;
Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex;

Mefenorex; Mephentermine; Mesocarb; Metamfetamine(d-); p-Methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

b: Specified Stimulants.

Including, but not limited to:

Benzfetamine;
Cathine**;
Cathinone and its analogues, e.g. mephedrone,

methedrone, and α- pyrrolidinovalerophenone; Dimethylamphetamine;
Ephedrine***;
Epinephrine**** (adrenaline);

Etamivan;
Etilamfetamine;
Etilefrine;
Famprofazone;
Fenbutrazate;
Fencamfamin;
Heptaminol;
Hydroxyamfetamine (parahydroxyamphetamine); Isometheptene;

Levmetamfetamine;
Meclofenoxate; Methylenedioxymethamphetamine; Methylephedrine***;
Methylhexaneamine (dimethylpentylamine); Methylphenidate;

Nikethamide;
Norfenefrine;
Octopamine;
Oxilofrine (methylsynephrine); Pemoline;

Pentetrazol;
Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****;
Selegiline;

6

SUBSTANCES & METHODS

PROHIBITED IN-COMPETITION

Sibutramine;
Strychnine;
Tenamfetamine (methylenedioxyamphetamine); Tuaminoheptane;

and other substances with a similar chemical structure or similar biological effect(s).

Except:

• Clonidine
• Imidazole derivatives for topical/ophthalmic use and

S7 NARCOTICS

Prohibited:

Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone;

Morphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine.

*

**

those stimulants included in the 2016 Monitoring Program*.

Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2016 Monitoring Program, and are not considered Prohibited Substances.
Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

S8

CANNABINOIDS

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

Prohibited:

  • Natural, e.g. cannabis, hashish and marijuana, or synthetic Δ9-tetrahydrocannabinol (THC).
  • Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210.S9 GLUCOCORTICOIDS
    All glucocorticoids are prohibited when adminis-

    tered by oral, intravenous, intramuscular or rectal routes.

7

P1 ALCOHOL
Alcohol (ethanol) is prohibited In-Competition only,

in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.

P2 BETA-BLOCKERS
Beta-blockers are prohibited In-Competition

only, in the following sports, and also prohibited Out-of-Competition where indicated.

  • Archery (WA)*
  • Automobile (FIA)
  • Billiards (all disciplines) (WCBS)
  • Darts (WDF)
  • Golf (IGF)
  • Shooting (ISSF, IPC)*
  • Skiing/Snowboarding (FIS) in ski jumping, freestyleaerials/halfpipe and snowboard halfpipe/big air
  • Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and withoutfins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight apnoea.

    *Also prohibited Out-of-Competition Including, but not limited to:

  • Air Sports (FAI)
  • Archery (WA)

• Automobile (FIA)
• Powerboating (UIM)

8

Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol;

Labetalol; Levobunolol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol; Timolol.

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

www.wada-ama.org

 

THE 2016 MONITORING PROGRAM

The following substances are placed on the 2016 Monitoring Program:

1. Stimulants: In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.

2. Narcotics: In-Competition only: Mitragynine and tramadol.

3. Glucocorticoids: In-competition (by routes of administration other than oral, intravenous, intramuscular or rectal) and Out-of-

Competition (all routes of administration) 4. Telmisartan: In and Out-of-Competition

The World Anti-Doping Code (Article 4.5) states: “WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport.